Observational Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Dec 7, 2023; 29(45): 5962-5973
Published online Dec 7, 2023. doi: 10.3748/wjg.v29.i45.5962
Table 1 Characteristics of study participants according to the quartiles of muscle strength

Q1
Q2
Q3
Q4
P for trend
N (unweighted)4305 4347 4397 4300
Age (yr)55.9 ± 0.449.2 ± 0.444.6 ± 0.339.9 ± 0.2< 0.001
Sex (men)45.2 (1.0)45.9 (0.9)46.2 (0.9)48.0 (0.9)0.172
Current smoker13.6 (0.7)16.6 (0.7)17.7 (0.7)20.3 (0.8)< 0.001
Physical activity38.5 (1.0)46.4 (1.0)51.1 (0.9)53.1 (0.9)< 0.001
Income (lowest quartile)28.8 (1.0)16.5 (0.7)10.7 (0.6)8.0 (0.5)< 0.001
Education (≤ 12 yr)45.4 (1.2)28.1 (0.9)16.9 (0.7)8.5 (0.5)< 0.001
BMI (kg/m2)26.0 ± 0.124.7 ± 0.123.5 ± 0.121.8 ± 0.1< 0.001
Waist circumference (cm)88.0 ± 0.284.0 ± 0.280.5 ± 0.276.3 ± 0.2< 0.001
Handgrip strength (kg)21.8 ± 0.227.8 ± 0.231.2 ± 0.235.6 ± 0.2< 0.001
Muscle strength (handgrip strength/body mass index)0.8 ± 0.011.1 ± 0.011.3 ± 0.011.6 ± 0.01< 0.001
Systolic BP (mmHg)122.7 ± 0.4118.2 ± 0.3115.2 ± 0.3112.1 ± 0.3< 0.001
Diastolic BP (mmHg)75.3 ± 0.275.8 ± 0.275.2 ± 0.274.2 ± 0.2< 0.001
AST (IU/L)24.5 ± 0.223.1 ± 0.221.5 ± 0.220.2 ± 0.1< 0.001
ALT (IU/L)26.0 ± 0.524.2 ± 0.421.0 ± 0.318.4 ± 0.2< 0.001
Total cholesterol (mg/dL)191.4 ± 0.7194.3 ± 0.7194.1 ± 0.6188.8 ± 0.6< 0.001
HDL-C (mg/dL)47.4 ± 0.249.9 ± 0.251.6 ± 0.254.0 ± 0.2< 0.001
LDL-C (mg/dL)115.0 ± 0.7116.9 ± 0.6116.5 ± 0.6112.3 ± 0.5< 0.001
Triglycerides (mg/dL)145.6 ± 2.0137.5 ± 2.0130.1 ± 1.9112.5 ± 1.6< 0.001
Fasting glucose (mg/dL)106.1 ± 0.5100.8 ± 0.497.6 ± 0.493.8 ± 0.3< 0.001
HbA1c (%)5.9 ± 0.025.7 ± 0.015.6 ± 0.015.4 ± 0.01< 0.001
hs-CRP (mg/L)1.7 ± 0.041.2 ± 0.041.1 ± 0.030.8 ± 0.03< 0.001
Obesity 56.7 (0.9)44.0 (1.0)28.7 (0.8)11.6 (0.6)< 0.001
Hypertension45.4 (1.0)30.5 (0.8)21.5 (0.7)12.4 (0.6)< 0.001
Diabetes mellitus22.5 (0.7)13.1 (0.6)7.8 (0.4)3.9 (0.3)< 0.001
Dyslipidemia31.8 (0.9)28.1 (0.9)21.2 (0.7)14.1 (0.6)< 0.001
Table 2 Odds ratios (95% confidence intervals) of metabolic dysfunction-associated fatty liver disease according to the categories of muscle strength
Muscle strength
Model 1
Model 2
Model 3
Total
    Q13.63 (3.34–3.95)3.24 (2.94–3.58)1.92 (1.70–2.16)
    Q2–Q41 (reference)1 (reference)1 (reference)
    P value
    Q19.12 (7.98–10.41)8.61 (7.41–10.01)3.12 (2.64–3.69)
    Q24.92 (4.29–5.64)4.75 (4.10–5.50)2.19 (1.85–2.58)
    Q32.48 (2.17–2.84)2.42 (2.10–2.78)1.41 (1.22–1.65)
    Q41 (reference)1 (reference)1 (reference)
    P for trend< 0.001< 0.001< 0.001
Men
    Q13.51 (3.02–4.09)3.31 (2.80–3.90)2.05 (1.70–2.47)
    Q2–Q41 (reference)1 (reference)1 (reference)
    P value< 0.001< 0.001
    Q17.30 (5.67–9.39)7.20 (5.52–9.38)2.88 (2.20–3.78)
    Q23.68 (2.83–4.78)3.68 (2.82–4.80)1.75 (1.32–2.31)
    Q32.02 (1.54–2.66)2.03 (1.55–2.68)1.23 (0.93–1.63)
    Q41 (reference)1 (reference)1 (reference)
    P for trend< 0.001< 0.001< 0.001
Women
    Q14.20 (3.74–4.71)3.17 (2.79–3.60)1.76 (1.47–2.10)
    Q2–Q41 (reference)1 (reference)1 (reference)
    P value< 0.001< 0.001< 0.001
    Q111.76 (9.87–14.02)9.14 (7.56–11.05)3.09 (2.43–3.92)
    Q26.09 (5.15–7.20)5.30 (4.47–6.30)2.52 (2.05–3.10)
    Q32.76 (2.34–3.26)2.59 (2.20–3.06)1.52 (1.25–1.85)
    Q41 (reference)1 (reference)1 (reference)
    P for trend< 0.001< 0.001< 0.001
Table 3 Subgroup analysis for the association between muscle strength and metabolic dysfunction-associated fatty liver disease

Muscle strength
OR (95%CI)
P for interaction
Sex0.126
    MenQ2–Q41 (reference)
Q12.05 (1.70–2.47)
    WomenQ2–Q41 (reference)
Q11.76 (1.47–2.10)
Age0.057
    < 65 yrQ2–Q41 (reference)
Q11.97 (1.70–2.29)
    ≥ 65 yrQ2–Q41 (reference)
Q11.74 (1.44–2.09)
Obesity0.264
    NoQ2–Q41 (reference)
Q11.63 (1.36–1.96)
    YesQ2–Q41 (reference)
Q12.09 (1.75–2.48)
Diabetes mellitus0.622
    NoQ2–Q41 (reference)
Q11.97 (1.72–2.26)
    YesQ2–Q41 (reference)
Q11.71 (1.33–2.22)
Table 4 Association between muscle strength and probable liver fibrosis assessed using fibrosis-4 among patients with metabolic dysfunction-associated fatty liver disease
Muscle strengthOR (95%CI)


Model 1
Model 2
Model 3
1.3 ≤ FIB-4 < 2.67
    Q12.67 (2.35–3.02)0.96 (0.82–1.12)1.03 (0.87–1.21)
    Q2–Q41 (reference)1 (reference)1 (reference)
    P value< 0.0010.5880.773
    Q14.09 (3.50–4.79)0.89 (0.72–1.09)1.01 (0.81–1.26)
    Q22.31 (2.00–2.66)0.85 (0.71–1.01)0.94 (0.78–1.13)
    Q31.67 (1.43–1.94)0.97 (0.81–1.16)1.04 (0.86–1.25)
    Q41 (reference)1 (reference)1 (reference)
    P for trend< 0.0010.117 0.809
FIB-4 ≥ 2.67
    Q14.71 (3.38–6.56)1.72 (1.19–2.50)1.83 (1.25–2.69)
    Q2–Q41 (reference)1 (reference)1 (reference)
    P value< 0.0010.0040.002
    Q18.13 (4.74–13.95)1.68 (0.89–3.17)1.85 (0.92–3.74)
    Q22.25 (1.22–4.15)0.78 (0.41–1.47)0.82 (0.41–1.66)
    Q32.20 (1.18–4.13)1.26 (0.65–2.46)1.31 (0.65–2.65)
    Q41 (reference)1 (reference)1 (reference)
    P for trend< 0.0010.1130.073